Grufity logo
Grufity logo
KTTA

KTTA - Pasithea Therapeutics Corp. Stock Price, Fair Value and News

$0.51-0.05 (-8.93%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

70/100

KTTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

KTTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KTTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTTA Price Action

Last 7 days

-3.4%

Last 30 days

-28.2%

Last 90 days

-34.9%

Trailing 12 Months

-29.1%

KTTA RSI Chart

KTTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KTTA Valuation

Market Cap

14.0M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

19.12

EV/EBITDA

1.86

Price/Free Cashflow

-0.82

KTTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KTTA Fundamentals

KTTA Revenue

Revenue (TTM)

730.3K

Rev. Growth (Yr)

853.2%

Rev. Growth (Qtr)

147.26%

KTTA Earnings

Earnings (TTM)

-19.7M

Earnings Growth (Yr)

19.47%

Earnings Growth (Qtr)

71.62%

KTTA Profitability

EBT Margin

-2702.22%

Return on Equity

-36%

Return on Assets

-35.02%

Free Cashflow Yield

-121.31%

KTTA Investor Care

Shares Dilution (1Y)

821.90%

Diluted EPS (TTM)

-1.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026730.3K---
2025317.2K257.2K225.5K327.2K
2024493.8K572.2K515.5K423.2K
2023468.8K451.0K433.2K415.4K
2022---486.6K
2021----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Pasithea Therapeutics Corp.

KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
 CEO
 WEBSITEpasithea.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Pasithea Therapeutics Corp. Frequently Asked Questions

KTTA is the stock ticker symbol of Pasithea Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Pasithea Therapeutics Corp. is 13.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, KTTA's PE ratio (Price to Earnings) is -0.71 and Price to Sales (PS) ratio is 19.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTTA PE ratio will change depending on the future growth rate expectations of investors.